FLT3 and acute myeloid leukemia: Recurrent driver mutations in FLT3 occur in approximately one-third of patients with de novo AML as internal tandem duplications (ITD) in the juxtamembrane domain or point mutations in the activation loop of the tyrosine kinase domain (Fig. 1a), which are screened for in routine diagnostics of AML32.